TICKERNOMICS Sign up
Last Update: 2024-03-28 02:15:41
ATHERSYS INC / NEW ( ATHX ) https://www.athersys.com
0.01USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
-99.49%
ATHX
SPY
32.74%
-99.98%
ATHX
SPY
92.93%
-99.98%
ATHX
SPY
224.41%
-99.99%
ATHX
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
0.16
7.58
0.14
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.00
0.89
-0.00
-19363.94
0.00
-0.19
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-15877.55
100.00
-22498.88
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
-4.2717
318.34
135.81
-2.29
Other Earnings and Cash Flow Stats:
ATHERSYS INC / NEW ( ATHX ) Net Income TTM ($MM) is -39.80
ATHERSYS INC / NEW ( ATHX ) Operating Income TTM ($MM) is -51.81
ATHERSYS INC / NEW ( ATHX ) Owners' Earnings Annual ($MM) is -24.93
ATHERSYS INC / NEW ( ATHX ) Current Price to Owners' Earnings ratio is -0.01
ATHERSYS INC / NEW ( ATHX ) EBITDA TTM ($MM) is -50.34
ATHERSYS INC / NEW ( ATHX ) EBITDA Margin is -22498.88%
Capital Allocation:
ATHERSYS INC / NEW ( ATHX ) has paid 0.00 dividends per share and bought back -12.547 million shares in the past 12 months
ATHERSYS INC / NEW ( ATHX ) has reduced its debt by 0.248 million USD in the last 12 months
Capital Structure:
ATHERSYS INC / NEW ( ATHX ) Interest-bearing Debt ($MM) as of last quarter is 8
ATHERSYS INC / NEW ( ATHX ) Annual Working Capital Investments ($MM) are -8
ATHERSYS INC / NEW ( ATHX ) Book Value ($MM) as of last quarter is -37
ATHERSYS INC / NEW ( ATHX ) Debt/Capital as of last quarter is -36%
Other Balance Sheet Stats:
ATHERSYS INC / NEW ( ATHX ) has 1 million in cash on hand as of last quarter
ATHERSYS INC / NEW ( ATHX ) has 38 million of liabilities due within 12 months, and long term debt 10 as of last quarter
ATHERSYS INC / NEW ( ATHX ) has 24 common shares outstanding as of last quarter
ATHERSYS INC / NEW ( ATHX ) has 0 million USD of preferred stock value
Academic Scores:
ATHERSYS INC / NEW ( ATHX ) Altman Z-Score is -152.84 as of last quarter
ATHERSYS INC / NEW ( ATHX ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
ATHERSYS INC / NEW ( ATHX ) largest shareholder is BlackRock Inc owning 450092 shares at 0.00 ($MM) value
Macleod ivor(Chief Financial Officer) Executed Type F Transaction for -1292 shares of ATHERSYS INC / NEW ( ATHX ) for the amount of $1072.36 on 2022-03-17
0.77% of ATHERSYS INC / NEW ( ATHX ) is held by insiders, and 4.43% is held by institutions
ATHERSYS INC / NEW ( ATHX ) went public on 2007-06-12
Other ATHERSYS INC / NEW ( ATHX ) financial metrics:
FCF:-35.94
Unlevered Free Cash Flow:-36.76
EPS:-0.62
Operating Margin:-15877.55
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:41.45
Beta:-2.29
Buffet's Owners Earnings:-24.93
Price to Owner's Earnings:-0.01
About ATHERSYS INC / NEW ( ATHX ) :
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. The company was founded in 1995 and is headquartered in Cleveland, Ohio.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.